REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that its Chief Financial Officer Fred Driscoll will present a company update at the BIO CEO Investor Conference at the Waldorf Astoria Hotel Tuesday, February 12, 2008 at 2:00 pm E.T.
The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at http://www.genelabs.com or through the following URL: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=GNLB&item_id=1752337 The presentation will also be available for replay after the presentation for a limited time.
About Genelabs Technologies
Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program. We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit http://www.genelabs.com.
Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.
Contact: Frederick W. Driscoll
Chief Financial Officer
Phone: 650-562-1424
CONTACT: Frederick W. Driscoll, Chief Financial Officer of Genelabs
Technologies, Inc., +1-650-562-1424
Web site: http://www.genelabs.com/
